5月1日，生物技术巨头渤健公布2025财年第一季度财报。财报显示：Q1总营收达24.3亿美元，同比增长6.2%，远超市场预期的22.3亿美元，主要得益于多发性硬化症（MS）和阿尔茨海默病药物销售增长。
调整后净利润为4.43亿美元，较上年同期下滑。每股收益（EPS）3.02美元，低于去年同期的3.67美元，同比下降17.7%，未达市场预期，主要受到研发投入增加及一次性支出拖累。
渤健预计全年非 GAAP 摊薄每股收益在 14.50 美元至 15.50 美元之间，其中包含前期交易款项带来的约 0.95 美元的影响，同时因外汇因素带来 0.20 美元的收益改善。
预计按固定汇率计算，2025年全年总营收将较 2024 年下降个位数百分比 。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.